Risks Of Blood Substitute Drugs Merit Return To Toxicology Studies – JAMA
Executive Summary
The toxicities of developmental hemoglobin-based oxygen carriers must be defined in preclinical animal testing replicating the products' known toxicities in humans before further humans trials are allowed to proceed, the authors of a study published April 28 in the Journal of the American Medical Association argue
You may also be interested in...
Privately-held NormOxys Raises $17.5 Million Series B To Further Develop Its Novel "Oxyren" Program
The money, provided by returning backer Index Ventures and new investor Care Capital, will support clinical development of NormOxys' lead drug candidate through proof-of-concept testing.
Sponsors Should Disclose Trial Data Even During Development, JAMA Says
Product sponsors need to publicly disclose more data about their products while they are in development in order to protect patients from unnecessary risk, authors of a study published April 28 in the Journal of the American Medical Association posit
Sponsors Should Disclose Trial Data Even During Development, JAMA Says
Product sponsors need to publicly disclose more data about their products while they are in development in order to protect patients from unnecessary risk, authors of a study published April 28 in the Journal of the American Medical Association posit